Dizal (Jiangsu) Pharmaceutical Co., Ltd.
3 clinical trials · Sponsor
◉ Watch Dizal (Jiangsu) Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (NCT07182682) | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 2025-12-01 |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) (NCT07079475) | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 2025-07-30 |
| A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants (NCT05176873) | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 2021-12-09 |
Track Dizal (Jiangsu) Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.